The global pain management devices market size was valued at USD 5.54 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 9.0% from 2020 to 2027. The increasing cases of chronic diseases is one of the key factors expected to contribute to the growth of the market over the forecast period. The growing prevalence of lifestyle disorders, such as obesity and diabetes, has increased the demand for muscle and nerve stimulators, thereby augmenting the market growth. The rising cancer cases are expected to further increase product demand over the forecast period. Moreover, the high prevalence of musculoskeletal disorders, such as arthritis, osteoarthritis, orthopedic degenerative disorders, and rheumatoid arthritis, and a resultant rise in cases of chronic pain and inability to carry out routine tasks, will boost product demand.
For instance, according to the CDC, over 54 million cases of arthritis were recorded in the U.S. in 2019, making it the primary reason for work disability. This has fueled the demand for pain management stimulators to manage chronic pain. The ineffectiveness of oral drugs is boosting patients to look for alternative treatment options, such as pain management devices. Moreover, the lack of preference for surgeries is one of the factors boosting demand.
The high costs associated with hospitalization have increased the need for a reduced hospital stay and the need to shift to less expensive care settings, thus boosting product demand. For instance, the average hospital stay cost accounted for around USD 15,734 in 2018. Moreover, technological advancements are anticipated to drive further growth. For instance, in September 2020 Boston Scientific launched WaveWriter Alpha Spinal Cord Stimulator Systems for personalized pain relief. In June 2020, Abbott partnered with Tandem Diabetes Care to develop integrated diabetes solutions.
However, the COVID-19 outbreak affected most of the sectors including the medical device industry. Nationwide lockdowns have impacted patients who specifically relied on exercise programs or PT as a pain management regimen. Moreover, many elective procedures, in-person patient visits have been suspended or delayed, which is expected to increase the demand for at-home pain treatment. In April 2020, Omron added a new Focus TENS Therapy device for the knee to its existing lineup of drug-free pain management products.
The neurostimulation segment held the largest revenue share of 57.5% in 2019. The growth can be attributed to the increased prevalence of neurological disorders. These neurostimulators play a crucial role in treating chronic pain, Parkinson’s disease, epilepsy, movement disorders, and depression. In addition, certain factors like escalating product demand, the introduction of technologically advanced products, and the growing geriatric population are anticipated to boost the segment growth.
Radiofrequency ablation is expected to register the fastest growth over the forecast period owing to its wide application in pain management, surgical oncology, gynecology, cardiology & cardiac rhythm management, and cosmetology. Radiofrequency ablation treatment is more beneficial than open surgery in treating patients with multiple tumors, which fuels its demand. Technological advancements in the field are also boosting segment growth. In June 2020, Boston Scientific launched a tool to monitor the effect of radiofrequency energy delivery during cardiac ablation procedures called DIRECTSENSE.
The neuropathic pain segment led the market with the maximum revenue share of over 31% in 2019. The growth can be attributed to the growing prevalence of the target population and increasing initiatives by the industry players. According to a report published in 2019 by the CDC, 65% of Americans aged 65 years or above suffered from chronic pain. In addition, neuropathic pain affects 3-17% of adults. The aforementioned factors are expected to propel segment growth.
The cancer segment is expected to register the fastest growth over the forecast period. The rising cancer cases have led to an increase in the demand for pain management devices to reduce the pain caused due to nerve compression, mainly because of the tumor compressing and other variables depending upon cancer’s progression. Moreover, the prevalence of genetic diseases, such as Acute Lymphoblastic Leukemia (ALL), is also expected to drive market growth during the forecast period. According to a report published by the National Cancer Institute, an estimated 5930 new cases of ALL were diagnosed and an estimated 1500 deaths were recorded in 2019.
North America accounted for the largest revenue share of 46.9% of the global market owing to the favorable healthcare infrastructure, which facilitates easy access to advanced pain management devices. Moreover, increasing government initiatives, such as the Precision Medicine and Affordable Care Act, along with a well-planned reimbursement scenario in this region is contributing to market growth.
Furthermore, the presence of key players in the region is expected to drive the market. Most of the companies in the region are involved in strategic initiatives for obtaining a higher market share. For instance, in May 2019, Abbott partnered with the U.S. National Institutes of Health (NIH) for the development of unique insights and driving applications of various neuromodulation therapies.
The market in Asia Pacific is anticipated to grow at the fastest CAGR during the forecast period. This growth can be attributed to R&D investments to produce technologically advanced healthcare treatment options. Moreover, the presence of several trade agreements is supporting market growth in the region. For instance, the Asia Pacific Trade Agreement (APTA) between China, Bangladesh, India, Lao PDR, Republic of Korea, Mongolia, and Sri Lanka has promoted trade liberalization and widened the import and export opportunities amongst participating nations.
The key companies have undertaken several strategic initiatives, such as technology innovation, partnership, regional expansion, and mergers and acquisitions, to strengthen their market position. For instance, in August 2020, Medtronic announced the commercial launch of its FDA-approved neurostimulator, called the InterStim Micro Neurostimulator.
The implant was meant for Sacral Neuromodulation (SNM) therapy to help patients gain effective bladder and bowel control. In October 2020, Smiths Medical launched the CADD-Solis ambulatory infusion pump version 4.2. This new version of the wireless bi-directional communication pump will help integrate pain management data with the EMR records of the patient. Some of the prominent players in the pain management devices market include:
Smiths Medical
B. Braun Melsungen AG
Baxter
Boston Scientific Corp.
Colfax Corp.
Medtronic Plc
Nevro Corp.
Abbott
Stryker
Omron Healthcare, Inc.
Stimwave LLC
Report Attribute |
Details |
The market size value in 2020 |
USD 5.96 billion |
The revenue forecast in 2027 |
USD 10.86 billion |
Growth Rate |
CAGR of 9.0% |
Base year for estimation |
2019 |
Historical data |
2016 - 2018 |
Forecast period |
2020 - 2027 |
Quantitative units |
Revenue in USD million and CAGR from 2016 to 2027 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments covered |
Product, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country Scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; The Netherlands; Japan; China; India; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia |
Key Companies Profiled |
Smiths Medical; B. Braun Melsungen AG; Baxter; Boston Scientific Corp.; Colfax Corp.; Medtronic Plc; Nevro Corp.; Abbott; Stryker; Omron Healthcare, Inc.; Stimwave LLC |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global pain management devices market report on the basis of product, application, and region:
Product Outlook (Revenue, USD Million, 2016 - 2027)
Electrical Stimulators
TENS
Others
Radiofrequency Ablation
Analgesic Infusion Pumps
Intrathecal Infusion Pumps
External Infusion Pumps
Neurostimulation
Spinal Cord Stimulators
Deep Brain Stimulators
Sacral Neurostimulators
Others
Application Outlook (Revenue, USD Million, 2016 - 2027)
Cancer
Neuropathic Pain
Facial & Migraine
Musculoskeletal Disorder
Trauma
Others
Regional Outlook (Revenue, USD Million, 2016 - 2027)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
The Netherlands
Asia Pacific
Japan
China
India
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
b. The global pain management devices market size was estimated at USD 5.54 billion in 2019 and is expected to reach USD 5.96 billion in 2020.
b. The global pain management devices market is expected to grow at a compound annual growth rate of 9.0% from 2020 to 2027 to reach USD 10.86 billion by 2027.
b. North America dominated the pain management devices market with a share of 45.3% in 2019. This is attributable to favorable healthcare infrastructure, government initiatives, and well-planned reimbursement policies.
b. Some key players operating in the pain management devices market include B Braun Melsungen AG; Baxter International, Inc.; Boston Scientific Corp.; Codman and Shurtleff; DJO Global LLC; Pfizer, Inc.; Medtronic Plc; Smiths Medical; St. Jude Medical, Inc.; and Stryker Corp.
b. Key factors that are driving the pain management devices market growth include the high prevalence of diabetes, rising geriatric population base, and increasing cases of cancer.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.